Akter, Hafeza Yoo, Young Sook Park, Won Sang Kang, Min-Jung 2024-01-20T02:02:42Z 2024-01-20T02:02:42Z 2021-09-01 2017-03 1976-0280 https://pubs.kist.re.kr/handle/201004/123013 There is no early diagnosis marker for gastric cancer even though the gastric cancer is the second cause of deaths in East Asia. The aim of the current research is to develop a new diagnostic marker of gastric cancer. Commercially available ELISA kits were used to evaluate the peptide levels in plasma collected from Korean healthy and gastric cancer patients. About 1.5 fold decreased plasma cholecystokinin levels were measured in gastric cancer patients (n = 75) than in healthy controls (n = 36). Plasma cholecystokinin has no age, sex, and disease-dependent variation in control and patients sample. Receiver-operating characteristic curve analysis assessing the performance of cholecystokinin levels as the sensitivity of 94.7% and specificity of 100 % compared to healthy controls. These findings suggest plasma cholecystokinin as a useful biomarker for diagnosis of gastric cancer. English 한국바이오칩학회 Cholecystokinin as a Potent Diagnostic Marker for Gastric Cancer Article 10.1007/s13206-016-1103-x 1 BioChip Journal, v.11, no.1, pp.14 - 20 BioChip Journal 11 1 14 20 N scie scopus kci ART002206155 000397078700003 2-s2.0-85015974393 Biochemical Research Methods Chemistry, Analytical Nanoscience & Nanotechnology Biochemistry & Molecular Biology Chemistry Science & Technology - Other Topics Article GROWTH CARCINOGENESIS NEUROTENSIN BIOMARKERS PROTEOMICS DISCOVERY Gastric cancer Biomarker ELISA CCK Early diagnosis